CD8 PET Imaging in Metastatic Solid Tumours

"89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later. All patients will undergo a 89Zr-Df-crefmirlimab PET scan at baseline and after treatment with the PD-1 antibody. All patients participating in this imaging trial will undergo preferably 2 but at least one tumour biopsy. The biopsy procedure(s) will be performed after the 89Zr-Df-crefmirlimab PET scan at baseline and/or after the 89Zr-Df-crefmirlimab PET on-treatment.~After the first PET scan and tumour biopsy the patients will start treatment with PD-1 antibody nivolumab or cetrelimab."

Immunotherapy treatment with Nivolumab

Immunotherapy treatment with cetrelimab

89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later